Back to search
FDAFDA · Food and drugs·Recall number D-0355-2023

Diltiazem HCl in 0.7% Sodium Chloride Injection, 125 mg/125 mL (1 mg/mL), 125 mL Single-Dose Container bottle, packaged in 15 x 1 IV Bottles per carton, Rx Only, Nephron 503B Outsourcing Facility, 4500 12th St. Extension, West Columbia, SC 29172, NDC 69374-997-15.

Published March 8, 2023 · Recall initiated: February 22, 2023

Summary

FDA records drug Class II recall D-0355-2023, published March 8, 2023 and initiated February 22, 2023. Recalling firm: Nephron Sterile Compounding Center LLC; Status: Terminated; Reported quantity: 4,743 bottles; Lot: Lots: DS2053, Exp. 2/27/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Nephron Sterile Compounding Center LLC
Distributor
Nationwide in the USA
Lot
Lots: DS2053, Exp. 2/27/2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Diltiazem HCl in 0.7% Sodium Chloride Injection, 125 mg/125 mL (1 mg/mL), 125 mL Single-Dose Container bottle, packaged in 15 x 1 IV Bottles per carton, Rx Only, Nephron 503B Outsourcing Facility, 4500 12th St. Extension, West Columbia, SC 29172, NDC 69374-997-15. recalled?

Yes. FDA published recall D-0355-2023 on March 8, 2023. Reported hazard: Lack of Assurance of Sterility

What should I do if I have this product?

Voluntary: Firm initiated · Letter